Progress in defining multidrug resistance in leukemia

References

• Gottesman MM, Pastan I. Biochemistry of multi-drug resistance mediated by the multidrug transporter. Ann. Rev Biochem. 62,385–427 (1993).
   PubMed Web of Science ®Google Scholar
• Sharom FJ. The P-glycoprotein efflux pump: how does it transport drugs? Membrane Biol. 160(3), 161–175 (1997).
   Google Scholar
• Cordon-Cardo C, O'Brien JP, Casals D et al Multi-drug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood—brain barrier sites. Proc. Natl Acad. Sci. USA 86(2), 695–698 (1989).
   Google Scholar
• Cordon-Cardo C, O'Brien JP, Boccia J eta]. Expression of the multi-drug resistance gene product (P-glycoprotein) in human normal and tumor tissues. j klistochem. Cytochem. 38(9), 1277–1287 (1990).
   Google Scholar
• Bello-Reuss E, Ernest S, Holland OB, Hellmich MR. Role of multi-drug resistance P-glycoprotein in the secretion of aldosterone by human adrenal NCI-H295 cells. Arn. I Physiol Cell Physiol 278 (6), C1256—C1265 (2000).
   Google Scholar
• Van Kalken CK, Broxterman HJ, Pinedo HM etal Cortisol is transported by the multi-drug resistance gene product P-glycoprotein. Br. Cancer 67 (2), 284–289 (1993).
   Google Scholar
• Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular and pharmacological aspects of the multidrug transporter. Ann. Rev. Pharmacol Toxicol 39,361–398 (1999).
   PubMed Web of Science ®Google Scholar
• Ramachandra M, Ambudkar SV, Chen D etal Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry 37(14), 5010–5019 (1998).
   PubMed Web of Science ®Google Scholar
• Hrycyna CA, Ramachandra M, Ambudkar SV etal Mechanism of action of human P-glycoprotein ATPase activity. Photochemical cleavage during a catalytic transition state using orthovanadate reveals cross-talk between the two ATP sites. Biol. Chem. 273(27), 16631–16634 (1998).
   Google Scholar
• Loo TVV, Clarke DM. Vanadate trapping of nucleotide at the ATP-binding sites of human multi-drug resistance P-glycoprotein exposes different residues to the drug-binding site. Proc. Natl Acad. Sci. USA 99(6), 3511–3516 (2002).
   Google Scholar
• Loo TW, Bartlett MC, Clarke DM. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding. j Biol. Chem. 278 (16), 13603–13606 (2003).
   Google Scholar
• Varadi A, Szakacs G, Bakos E, Sarkadi B. P-glycoprotein and the mechanism of multi-drug resistance. Novartis Found. Symp. 243,54–65 (2002).
   PubMedGoogle Scholar
• Yang R, Cui L, Hou YX etal ATP binding to the first nucleotide binding domain of multi-drug resistance-associated protein plays a regulatory role at low nucleotide concentration, whereas ATP hydrolysis at the second plays a dominant role in ATP-dependent leukotriene C4 transport. Biol. Chem. 278(33), 30764–30771 (2003).
   Google Scholar
• van Helvoort A, Smith AJ, Sprong H etal MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Ce1187 (3), 507–517 (1996).
   Google Scholar
• Smit JJM, Schinkel AH, Moi CAAM etal Tissue distribution of the human MDR3 P-glycoprotein. Lab. Invest.71 (5), 638–649 (1994).
   Google Scholar
• Borst P, Evers R, Kool M, Wijnholds J. The multi-drug resistance protein family. Biochim. Biophys. Acta 1461(2), 347–357 (1999).
   Google Scholar
• Hipfner DR, Deeley RG, Cole SR Structural, mechanistic and clinical aspects of MRP1. Biochim. Biophys. Acta 1461 (2), 359–376 (1999).
   Google Scholar
• Manciu L, Chang XB, Buyse F etal Intermediate structural states involved in MRP1-mediated drug transport. Role of glutathione.Chem. 278(5), 3347–3356 (2003).
   Google Scholar
• Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B. The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett. 140–141,133-143 (2003).
   Google Scholar
• Konig J, Nies AT, Cui Y, Leier I, Keppler D. Conjugate export pumps of the multi-drug resistance protein (MRP) family: localization, substrate specificity and MRP2 mediated drug resistance. Biochim. Biophys. Acta 1461(2), 377–394 (1999).
   Google Scholar
• Hirohashi T, Suzuki H, Sugiyama Y. Characterization of the transport properties of cloned rat multi-drug resistance protein-associated protein 3 (MRP3). j Biol. Chem. 274(15), 15181–15185 (1999).
   Google Scholar
• Wijnholds J, de Lange EC, Scheffer GL etal Multi-drug resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. j Clin. Invest. 105(3), 279–285 (2000).
   Google Scholar
• Buehler M, Konig J, Brom M etal cDNA cloning of the hepatocyte canalicular isoform of the multi-drug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J. Biol. Chem. 271(25), 15091–15098 (1996).
   Google Scholar
• Paulusma CC, Bosma PJ, Zaman GJR etal Congenital jaundice in rats with a mutation in a multi-drug resistance-associated protein gene. Science271(5252), 1126–1128 (1996).
   PubMed Web of Science ®Google Scholar
• Ozvegy C, Litman T, Szakacs G et a/. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem. Biophys. Res. Gamin. 285(1), 111–117 (2001).
   Google Scholar
• Doyle LA, Yang W Abruzzo LV etal A multi-drug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl Acad. Sc]. USA 95(26), 15665–15670 (1998).
   Google Scholar
• Sargent JM, Williamson CJ, Maliepaard M, Elgie AW, Scheper RJ, Taylor CG. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. BE j .thematol. 115 (2), 257–262 (2001).
   Google Scholar
• van den Heuvel-Eibrink MM, Wiemer EA, Prins A etal Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia. Leukemia 16(5), 833–839 (2002).
   PubMed Web of Science ®Google Scholar
• Scheper RJ, Broxterman HJ, Scheffer GL eta]. Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multi-drug resistance. Cancer Res. 53(7),1475 (1993).
   Google Scholar
• List AF, Spier CS, Grogan TM eta]. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. B/ooc/87(6), 2464–2469 (1996).
   Google Scholar
• Scheffer GL, Wijngaard PL, Hens MJ etal The drug resistance-related protein LRP is the human major vault protein. Nature Med. 1(6), 578–582 (1995).
   Google Scholar
• Simon SM, Schindler M. Cell biological mechanisms of multi-drug resistance in tumors. Proc. Natl Acad. Sc]. USA 91(9), 3497–3504 (1994).
   Google Scholar
• ••Enlightening review that explicitlyexplains what happens to cells that develop multidrug resistance (MDR) and describes the ATP-driven drug efflux model as well as the compartmentali7ation, exocytosis, nuclear mechanisms and the pH hypothesis.
   Google Scholar
• Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52(4), 891–896 (1992).
   Google Scholar
• Lo YL, Liu Fl, Yang JM, Chemg JY. Reversal of multi-drug resistance to epirubicin by cyclosporin A in liposomes or intralipid. Anticancer Res. 21 (1A), 445–450 (2001).
   Google Scholar
• Smith AJ, Mayer U, Schinkel AH, Borst P. Availability of P5C833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. j Natl Cancer Inst. 90(15), 1161–1166 (1998).
   Google Scholar
• Loor F, Tiberggien F, Wanandy T, Didier A, Traber R. Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter. j Med. Chem. 45 (21), 4598–4612 (2002).
   Google Scholar
• Sonneveld P. Multi-drug resistance in haematological malignancies. .1. Intern. Med. 247(5), 521–534 (2000).
   Google Scholar
• •Focuses specifically on the reversal of MDR in clinical practice.
   Google Scholar
• Thomas H, Coley HM. Overcoming multi-drug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Conti-19110(2), 159–165 (2003).
   Google Scholar
• Ghetie MA, Ghetie V, Vitetta S. Anti-CD19 antibodies inhibit the function of the P-gp pump in multi-drug resistant B-lymphoma cell. Clin. Cancer Res. 5(12), 3920–3927 (1999).
   Google Scholar
• Maia RC, Wagner K, Cabral RII, Rumjanek VM. Heparin reverses rhodamine 123 extrusion by multi-drug resistant cells. Cancer Lett. 106(1), 101–108 (1996).
   Google Scholar
• Wang FS, Kobayashi H, Liang KW, Holland JF, Ohnuma T Retrovirus-mediated transfer of antiMDR1 ribozymes fully restores chemosensitivity of P-glycoprotein-expressing human lymphoma cells. Human Gene Ther. 10(7), 1185–1195 (1999).
   Google Scholar
• Beck WT, Grogan TM, Willman CL etal Methods to detect P-glycoprotein-associated multi-drug resistance in patients' tumors: consensus recommendations. Cancer Res. 56(13), 3010–3020 (1996).
   Google Scholar
• ••Describes the consensus recommendationsof detecting drug resistance by flow cytometric, imrnunohistochemical and molecular biological methods.
   Google Scholar
• KaraS. Zi É, Jakab K, Homolya L eta]. Calcein assay for multi-drug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia. Br. .thematol. 112(2), 308–314 (2001).
   Google Scholar
• Olson DP, Taylor BJ, Ivy SR Detection of MRP functional activity: calcein AM but not BCECF AM as a multi-drug resistance-related protein (MRP1) substrate. Cytomeby 46(2), 105–113 (2001).
   Google Scholar
• Legrand 0, Simonin G, Perrot JY, Zittoun R, Marie JR Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. B/ooc/91(12), 4480–4488 (1998).
   Google Scholar
• •Very comprehensive clinical study that uses calcein as a fluorescent probe to detect MDR.
   Google Scholar
• Martinez A, San Miguel JF, Valverde B etal Functional expression of MDR-1 in acute myeloid leukemia: correlation with the clinical-biological, immunophenotypical and prognostic disease characteristics. Ann. Hematol. 75(3), 81–86 (1997).
   Google Scholar
• Gsur A, Zochbauer S, Gotzl M, Kyrle PA, Lechner K, Pirker R. MDR1 RNA expression as a prognostic factor in acute myeloid leukemia: an update. Leuk. Lymphoma 12(1–2), 91–94 (1993).
   Google Scholar
• Ogretmen B, Barredo JC, Safa AR. Increased expression of lung resistance-related protein and multi-drug resistance-associated protein messenger RNA in childhood acute lymphoblastic leukemia. Pediatc Hematol. Oncol. 22(1), 45–49 (2000).
   Google Scholar
• Ross DD, Karp JE, Chen TT, Doyle LA. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. B/ooc/96(1), 365–368 (2000).
   Google Scholar
• Olesen LH, Norgaard JM, Pallisgaard N, Bukh A, Holdand P. Validation and clinical implication of a quantitative real-time PCR determination of MDRI gene expression: comparison with semi-quantitative PCR in 101 patients with acute myeloid leukemia. Eur.j .thematol. 70(5), 296–303 (2003).
   Google Scholar
• Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA. Expression of the human multi-drug resistance cDNA in insect cells generates a high-activity drug-stimulated membrane ATPase. Bid Chem. 267 (7), 4854–4858 (1992).
   Google Scholar
• Legrand 0, Perrot JY, Simonin G, Baudard M, Marie JR JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia. Blood 97(2), 502–508 (2001).
   Google Scholar
• HOHO Z, Homolya L, Davis CW, Sarkadi B. Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim. Biophys. Acta 1191(2), 384–388 (1994).
   Google Scholar
• •Well-documented methodological paper that was followed by several others that used calcein as a suitable probe for MDR detection.
   Google Scholar
• Raspadori D, Damiani D, Michieli M eta]. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome. .thematologica 87(11), 1135–1140 (2002).
   Google Scholar
• Mechetner EB, Schott B, Morse BS etal P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proc. Natl Acad. Sc]. 94(24), 12908–12913 (1997).
   Google Scholar
• •Describes a novel approach to detect conformational changes in P-glycoprotein by using different monoclonal antibody clones.
   Google Scholar
• Nagy H, Goda K, Arceci R, Cianfriglia M, Mechetner E, Szabó G Jr. P-glycoprotein conformational changes detected by antibody competition. Eur. j Biochem. 268(8), 2416–2470 (2001).
   Google Scholar
• Coda K, Nagy H, Mechetner E, Cianfriglia M, Szabó G Jr. Effects of ATP depletion and phosphate analogues on P-glycoprotein conformation in live cells. Eurj Biochem. 269,2672–2677 (2002).
   Google Scholar
• Goda K, Nagy H, Bene L et a/. Conformational heterogeneity of P-glycoprotein. Cancer Detect. Rev. 24(5), 415–421 (2000).
   Google Scholar
• Kappelmayer J, Karaszi É, Telek B, Jakob K. Pros and cons on how to measure multi-drug resistance in leukemias. Leuk. Lymphoma 43(4), 711–717 (2002).
   Google Scholar
• Kawahara M, Sokoto A, Miyashita T, Tamai I, Tsuji A. Physiologically based pharmacokinetics of digoxin in MDRla knockout mice. J. Pharrn. Sc]. 88(12), 1281–1287 (1999).
   Google Scholar
• Siddiqui A, Kerb R, Weale ME etal Association of multi-drug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl. Med. 348(15), 1442–1448 (2003).
   Google Scholar
• van den Heuvel-Eibrink MM, Wiemer EAC, de Boevere MJ et al MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. B/ooc/97(11), 3605–3611 (2001).
   Google Scholar
• Illmer T, Schuler US, Thiede C etal MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 62 (17), 4955–4962 (2002).
   Google Scholar
• Márián T, Szabó G, Goda K et a/. In vivo and in vitm multiracer analyses of P-glycoprotein expression-related multi-drug resistance. Eur J. Nucl. Med. Mal Imaging 30 (8), 1147–1154 (2003) .
   Google Scholar
• Kostakoglu L, Guc D, Canpmar H etal P-glycoprotein expression by Technetium-99m-MIBI scintigraphy in hematologic malignancy. J. Nucl. Med. 39(7), 1191–1197 (1998).
   Google Scholar
• Campos L, Oriol P, Sabiado 0, Guoyotat D. Simultaneous expression of P-glycoprotein and BCL-2 in acute myeloid leukemia blast cells. Leuk. Lymphoma 27(1–2), 119–125 (1997).
   Google Scholar
• Johnstone RVV, Cretney E, Smyth M. P-glycoprotein protects leukemia cells against caspase-dependent but not caspase-independent, cell death. B/ooc/93(3), 1075–1085 (1999).
   Google Scholar
• ••Carefully performed study that dissectsthe association of apoptosis with P-glycoprotein expression.
   Google Scholar
• Pallis M, Turzanski J, Higashi Y, Russel N. P-glycoprotein in acute myeloid leukemia: therapeutic implications of its association with both multi-drug resistant and apoptosis-resistant phenotype. Leuk. Lymphoma 43(6), 1121–1228 (2002).
   PubMedGoogle Scholar
• Gupta M, Kumar A, Dabadghao S. Resistance of bcr-abl positive acute lymphoblastic leukemia to daunorubicin is not mediated by MDR1 gene expression. Am. Hematol 71(3), 172–176 (2002).
   Google Scholar
• Zwaan CM, Kaspers GJL, Pieters R et al Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood 100 (9), 3352–3360 (2002).
   PubMedGoogle Scholar
• Leith CP, Kopecky KJ, Godwin J etal Acute myeloid leukemia in the elderly: assessment of multi-drug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. B/ooc/89(9), 3323–3329 (1997).
   Google Scholar